Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Nov 26:16:267-273.
doi: 10.2147/OAEM.S473627. eCollection 2024.

Droperidol Plus Diphenhydramine for Symptom Improvement in Suspected Cannabinoid Hyperemesis Syndrome: A Prospective Cohort Study

Quincy Chopra  1 , Vincent Peyko  2 , Jessica Annie Lee  3 , Leo Puhalla  3 , David J Gemmel  4 , Todd Bolotin  5   6
Affiliations
Clinical Trial

Droperidol Plus Diphenhydramine for Symptom Improvement in Suspected Cannabinoid Hyperemesis Syndrome: A Prospective Cohort Study

Quincy Chopra et al. Open Access Emerg Med. .

Abstract

Background: Cannabinoid Hyperemesis Syndrome (CHS) is characterized by recurrent, paroxysmal episodes of nausea, vomiting, and abdominal discomfort in chronic cannabis users. Optimized CHS treatment data remain limited. Recent prospective evidence have demonstrated haloperidol superiority over ondansetron. Retrospective data suggest the utility of droperidol, a dopamine antagonist like haloperidol, for treating acute CHS.

Objective: To prospectively assess the utility of droperidol plus diphenhydramine to mitigate common CHS symptoms.

Methods: This was a multicenter, prospective interventional study in the emergency department (ED). Participants were administered a study regimen of droperidol and diphenhydramine to treat CHS after enrollment. The primary outcome measure was the change in VAS scores within the droperidol prospective cohort. Symptoms of nausea, vomiting, and abdominal pain were measured using a visual analogue scale (VAS) up to 120 minutes. Secondary measures assessed include repeat visits to the ED within seven days.

Results: Amongst 47 droperidol participants, VAS for nausea and vomiting declined from baseline 8.3±2.0 to 3.1±3.3 at 30 minutes post treatment (p < 0.05), and 1.4±2.4 at 120 minutes (p < 0.05). For abdominal pain, VAS mean was 7.8±2.4 at baseline declining to 3.6±2.9 at 30 minutes (p < 0.05) and 1.7±2.9 at 120 minutes (p < 0.05). Return to the ED within 7 days following droperidol was 12.9% (n=47).

Conclusion: This trial shows significant improvement in symptoms from baseline, 30 and 120 minutes post-treatment and return to the ED within a week post treatment with the study regimen.

Keywords: abdominal pain; cannabinoid hyperemesis syndrome; droperidol; nausea; vomiting.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

    1. Allen GH, de Moore GM, Heddle R, et al. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis use. Gut. 2004;53:1566–1570. doi:10.1136/gut.2003.036350 - DOI - PMC - PubMed
    1. Lee C, Greene SL, Wong A. The utility of droperidol in the treatment of cannabinoid hyperemesis syndrome. Clin Toxicol. 2019;57:773–777. doi:10.1080/15563650.2018.1564324 - DOI - PubMed
    1. Ruberto AJ, Sivilotti ML, Forrester S, et al. Intravenous haloperidol versus ondansetron for cannabis hyperemesis syndrome (HaVOC): a randomized, controlled trial. Ann Emerg Med. 2021;77:613–619. doi:10.1016/j.annemergmed.2020.08.021 - DOI - PubMed
    1. Bonnet U. Cannabis-related cyclic/episodic hyperemesis conditions: from suspected to definitive cannabinoid hyperemesis syndrome. Med Princ Pract. 2022;31:497–498. doi:10.1159/000525991 - DOI - PMC - PubMed
    1. Kheifets M, Karniel E, Landa D, et al. Resolution of cannabinoid hyperemesis syndrome with benzodiazepines: a case series. Isr Med Assoc J. 2019;21:404–407. - PubMed

LinkOut - more resources